	US 11,866,420 B2
	Hydrochloride salt forms of a sulfonamide structured kinase inhibitor
David Jonaitis, Brookston, IN (US); and Oskari Karjalainen, Helsinski (FI)
Assigned to Aurigene Oncology Limited, Karnataka (IN)
Appl. No. 17/273,774
Filed by Aurigene Oncology Limited, Karnataka (IN)
PCT Filed Sep. 5, 2019, PCT No. PCT/FI2019/050629 § 371(c)(1), (2) Date Mar. 5, 2021, PCT Pub. No. WO2020/049217, PCT Pub. Date Mar. 12, 2020.
Claims priority of application No. 20185743 (FI), filed on Sep. 6, 2018.
Prior Publication US 2021/0332028 A1, Oct. 28, 2021
Int. Cl. C07D 403/04 (2006.01)

CPC C07D 403/04 (2013.01) [C07B 2200/13 (2013.01)]

14 Claims

1. A compound which is hydrochloride salt of N-(2′,4′-difluoro-5-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)-[1,1′-biphenyl]-3-yl)cyclopropanesulfonamide (I), wherein the compound is in crystalline form.